| |
|
|
| |
Inhaled Pain Management
Products, Therapeutics, Markets and
Forecasts
|
Publication: May 2011
Product Code: NPM533R
|
As life expectancy in the developed world increases and
populations age, the incidence and associated morbidity of
chronic and acute pain is increasing and placing a higher
level of emphasis on pain management as a quality-of-life
issue for patients and their families. Responding to this
trend, drug developers are increasingly turning to inhalable
formulations of pain management drugs. Because it has the
potential to improve drug therapy compliance, inhaled pain
drug delivery addresses a key healthcare issue – one that is
particularly problematic in aging populations and developing
economies. Several of these development programs involve
international partnerships designed to take advantage of
perceived opportunities in regional markets.
|
|
Highlights |
· Analyzes and evaluates
intranasal and orally inhaled pain management products
and pipeline candidates and assesses the market
potential for existing and probable future products
· Examines inhalation
product technology issues and evolving market factors
for inhaled pain management therapeutics
· Provides detailed
assessments of market segments and growth prospects
· Provides market data
and forecasts to 2015
· Profiles inhaled pain
management market sector participants, their
product development activities, business
strategies, and corporate alliances and
affiliations
|
|
Summary of Contents |
Executive Summary
The
Pain Management Market Opportunity
Evolution
in Pain Management Guidelines
Regional Factors in
Pain Management Practice
Pain Management Demand
Drivers
Competitive Landscape
Factors
Limiting Growth
Inhalation Technology,
Platforms and Design Factors
Drug
Formulations
Formulation Technologies
Excipients and Release Profiles
Oral Inhalation
Device Design Factors
Dry Powder Inhalers
Metered Dose Inhalers
Nebulizers
Intranasal Inhalation
Intranasal Delivery Pharmacokinetics
Intranasal
Device Characteristics
Performance Factors
Bioavailability
Dose Reproducibility
Active
Compound Stability
Key Near-Term Pain Markets
for Inhaled Drugs
Breakthrough Cancer Pain
Cluster Headaches
Migraine
Moderate to Severe
Pain
Inhaled Pain Management
Drugs - Analysis and Forecasts
Approved Drugs
AstraZeneca
GlaxoSmithKline
Mylan
Novex
Roxane
Roxro
Valeant
Development-Stage Drugs
Butorphanols
Fentanyls
Dihydroergotamines
Morphines
Perchlorperazine
Triptans
Market
Factors
Usability and Patient Preferences
Regulatory Issues
Patient Compliance
The Role
of CMOs/CSOs
Market Participant Profiles |
|
|
|
|
|
|
